

UC Irvine

UC Irvine Previously Published Works

Title

Genetics and Epigenetics of Human Retinoblastoma

Permalink

<https://escholarship.org/uc/item/94n354v1>

Journal

Annual Review of Pathology Mechanisms of Disease, 10(1)

ISSN

1553-4006

Authors

Benavente, Claudia A

Dyer, Michael A

Publication Date

2015-01-24

DOI

10.1146/annurev-pathol-012414-040259

Peer reviewed

Genetics and Epigenetics of Human Retinoblastoma

Claudia A. Benavente¹ and Michael A. Dyer^{1,2}

¹Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105; email: michael.dyer@stjude.org

²Howard Hughes Medical Institute, Chevy Chase, Maryland 20815

Annu. Rev. Pathol. Mech. Dis. 2015. 10:547–62

The *Annual Review of Pathology: Mechanisms of Disease* is online at pathol.annualreviews.org

This article's doi:
10.1146/annurev-pathol-012414-040259

Copyright © 2015 by Annual Reviews.
All rights reserved

Keywords

retinoblastoma, RB1, genetics, epigenetics, *RB1*

Abstract


Retinoblastoma is a pediatric tumor of the developing retina from which the genetic basis for cancer development was first described. Inactivation of both copies of the *RB1* gene is the predominant initiating genetic lesion in retinoblastoma and is rate limiting for tumorigenesis. Recent whole-genome sequencing of retinoblastoma uncovered a tumor that had no coding-region mutations or focal chromosomal lesions other than in the *RB1* gene, shifting the paradigm in the field. The retinoblastoma genome can be very stable; therefore, epigenetic deregulation of tumor-promoting pathways is required for tumorigenesis. This review highlights the genetic and epigenetic changes in retinoblastoma that have been reported, with special emphasis on recent whole-genome sequencing and epigenetic analyses that have identified novel candidate genes as potential therapeutic targets.

INTRODUCTION


Retinoblastoma is a rare, pediatric cancer of the developing retina that occurs either as an inherited or as a sporadic disease (**Figure 1**). Despite its rarity, it was through the study of retinoblastoma that Knudson (1) formulated the two-hit hypothesis, proposing that retinoblastoma requires two rate-limiting events and explaining the difference in age of diagnosis of bilateral versus unilateral patients (**Figure 2**). Knudson's hypothesis was confirmed when the *RB1* gene was cloned (2) and found to undergo biallelic inactivation in virtually all retinoblastoma tumors (2, 3). Since then, hundreds of genetic lesions in human cancer have been identified. These genetic lesions can be grouped into pathways with direct or indirect mechanistic links to many of the common cellular properties, or hallmarks of cancer, including activation of growth-signaling pathways, evasion of cell death and senescence, acquisition of limitless replicative potential, sustained angiogenesis, local tissue invasion, and metastasis (4). Thus, the rate of cancer progression is related to the kinetics of acquisition of multiple genetic lesions that ultimately confer the essential cellular properties of cancer.

In the retina, *RB1* inactivation confers limitless replicative potential to retinoblasts, and these preneoplastic cells must also evade cell death and senescence, sustain angiogenesis, activate growth-signaling pathways, invade the local ocular tissues, and metastasize. If individual genetic lesions in multiple cancer pathways are required to contribute to retinoblastoma's cellular properties, then they must occur rapidly because biallelic inactivation of *RB1* is rate limiting for tumorigenesis (1).


a Nonhereditary retinoblastoma



b Hereditary retinoblastoma



c Retinoblastoma without *RB1* mutations



d Retinoblastoma with *RB1* chromothripsis




Figure 1

Hereditary versus nonhereditary retinoblastoma. (a) In nonhereditary retinoblastoma, noncancerous cells show no defect in either copy of *RB1*; therefore, they require two hits in a single retinal cell lineage to inactivate both copies of the *RB1* gene. These hits can be mutations, promoter hypermethylation, or loss of heterozygosity (LOH). (b) In hereditary retinoblastoma, all cells in the body lack one of the functional copies of *RB1*, and tumors occur where the remaining copy is lost or inactivated by a somatic mutation, mitotic crossover (LOH), or promoter hypermethylation. (c) A small percentage of patients have no mutations in the *RB1* gene, some of whom will develop the disease through amplification of the *MYCN* gene. (d) A small percentage of patients present chromothripsis, including the *RB1* gene.




Figure 2

Genetic and epigenetic timeline of retinoblastoma.

RETINOBLASTOMA AND CHROMOSOMAL INSTABILITY


Evidence from molecular, cellular, and cytogenetic studies indicates that the RB1 protein is required for maintaining chromosomal stability (5–7). Therefore, *RB1* inactivation, which leads to chromosome instability (CIN) in cultured cells, could allow the secondary and tertiary mutations in key cancer pathways to be rapidly acquired. Thus, *RB1* inactivation could be rate limiting for retinoblastoma and still allow the cells to acquire all the hallmarks of cancer through genetic mechanisms.

Studies have suggested that loss of RB1 results in mitotic defects that can lead to aneuploidy, which in turn can contribute to CIN (5, 6, 8, 9) (**Figure 3a**). Indeed, most cancers have suppressed RB pathways, and CIN is an important hallmark of many of the most aggressive forms of sporadic human cancers (10). This relationship between RB1 loss and aneuploidy was further strengthened by recent mechanistic data showing RB has a direct role in maintaining proper chromosome cohesion, which is important for maintaining the fidelity of chromosome segregation during cytokinesis (5). We (11) directly validated the role of RB1 in regulating proper cohesion and segregation of chromosomes in human retinoblastoma. However, three independent xenografts from different patients provided little evidence of cumulative loss of chromosomes over time, and at least some retinoblastomas had no evidence of aneuploidy (11). These findings are consistent with other studies showing that subsets of human retinoblastomas have few chromosomal lesions and that xenografts and populations of cultured retinoblastomas show little genomic variation (12–15).

Recurrent Chromosomal Abnormalities in Retinoblastoma

Isochromosome 6p, a unique chromosomal abnormality, is found in 45% of retinoblastomas (16, 17). Other common chromosomal abnormalities observed in retinoblastoma include gain of regions of chromosome 1q (44%); monosomy of chromosome 16 (18%); gain of 1p (13%) and, less

a Genome instability model of tumor progression



b Epigenetic model of tumor progression




Figure 3

Models of tumor progression in retinoblastoma. (a) The role of the RB1 protein in maintaining proper chromosome cohesion makes it important for maintaining the fidelity of chromosome segregation during cytokinesis. Loss of RB1 could result in mitotic defects that lead to chromosome instability, allowing secondary and tertiary mutations in key cancer pathways. (b) RB1 has been implicated in regulating most major epigenetic processes. Loss of RB1 leads to chromatin remodeling, in which oncogenes that are normally repressed switch to active chromatin, tumor suppressors that are normally actively transcribed are repressed, or both. Abbreviation: meDNA, methylated DNA.

prevalent, loss of a sex chromosome; alterations in chromosomes 17 and 19; double minutes; and homogeneously staining regions (17–20). The karyotype abnormalities found in retinoblastoma have been thoroughly reviewed elsewhere (17, 21–24). Although these reports show that the patterns of chromosomal abnormality changes present in retinoblastoma are consistent, many of these studies were performed using retinoblastoma cell lines, not primary retinoblastoma tumors, opening the possibility for clonal expansion and selection of more aggressive tumor cells that are aneuploid. Indeed, although Potluri et al. (17) identified at least one chromosomal gain or loss




Figure 4

Recurrent genetic aberrations in retinoblastoma. Minimal chromosomal regions of gain and loss that have been validated by new technology and contain genes that are potential drivers of retinoblastoma progression.

in each of the 82 tumor karyotypes reviewed, later comparative genomic hybridization (CGH) studies on primary tumor material always found some tumors with no identifiable aneuploidy (25). The advent of new technology has allowed scientists to validate some key aberrations described in earlier years as well as identify candidate genes in those regions. A comprehensive summary of the karyotype, CGH, and microarray CGH data can be found in Corson & Gallie's review (25). The recurrent gains and losses we review here are minimal regions of gain and loss that have been validated by new technology since their initial report and contain genes that are potential drivers of retinoblastoma progression (**Figure 4**).

Isochromosome 6p: *E2F3* and *DEK*. Gains of 6p are the most common changes in retinoblastoma observed by CGH (54%) (25). The minimal region of gains on chromosome 6 was narrowed to band p22, and further gene expression analyses suggested *DEK* and *E2F3* as the potential targets of 6p gains in retinoblastoma (26, 27). *E2F3*, a family member of the E2F family of transcription factors, is regulated by the RB1 protein and is often overexpressed in cancer (28–31). *DEK* is related to chromatin reconstruction and gene transcription and plays an important role in cell apoptosis. High expression levels of *DEK* have been correlated with numerous human malignancies (32–34).

Chromosome 1q: *KIF14* and *MDM4*. Gains in chromosome arm 1q are the second most common chromosomal change in retinoblastoma (53% by CGH) (25). The minimal common region gained spans 1q31–q32, and two independent CGH studies associated gains in 1q with advanced tumors in older children (35, 36). The genes *KIF14* and *MDM4* have been validated in this region. Gene-specific analysis using fluorescence in situ hybridization confirmed that *KIF14* gain was present in all retinomas studied, whereas gain of *MDM4* was present in fewer cases (7).

KIF14 is a member of the kinesin superfamily of microtubule-associated motors that play important roles in intracellular transport and cell division (37). *KIF14* has been identified as a prognostic marker for gliomas and breast, lung, and ovarian cancers (38–41). Madhavan et al. (42) confirmed overexpression of *KIF14* in primary human retinoblastoma and showed that patients with an older age at diagnosis express significantly higher levels of the *KIF14* protein.

MDM4 inhibits cell cycle arrest and apoptosis by binding to the transcriptional activation domain of the p53 tumor suppressor protein and inhibiting its activity. Analysis of human retinoblastoma revealed that *MDM4* was amplified in 65% of the tumors and negatively correlated with p53 levels (43). This finding provided an explanation for how retinoblastomas bypass the p53 pathway in a cancer that was previously thought to arise from an intrinsically death-resistant cell (43).

Chromosome 16: *CDH11*. CGH studies identified loss of all chromosome 16 or 16q in 32% of retinoblastoma cases and identified *CDH11* as the candidate tumor suppressor in this region (25). Chromosomal losses in this region in invasive ductal and lobular breast carcinomas have also been characterized (44). *CDH11* encodes cadherin-11, an integral membrane protein that mediates calcium-dependent cell-cell adhesion. Loss of *CDH11* in retinoblastoma cells may lead to tumor progression and invasion of the optic nerve (45).

RETINOBLASTOMA GENOMICS AND EPIGENOMICS

Whole-Genome Sequencing of Retinoblastoma

Whole-genome sequencing (WGS) of four retinoblastomas and their paired germline DNA samples showed no genetic lesions in known tumor suppressor genes or oncogenes other than *RBI* (11). More importantly, an orthotopic xenograft derived from one of the primary tumors showed no evidence of clonal variation or new coding-region mutations (11). Results from a larger tumor cohort used to validate and determine the rate of recurrence of these mutations indicated that only *BCOR* was recurrently mutated in retinoblastoma (6 of 46 samples, 13%). Five samples had *BCOR* mutations that resulted in premature truncation of the encoded protein, and one sample had a focal gene deletion. This finding suggests that retinoblastoma's genome is more stable than previously believed and that very few genetic lesions are required for retinoblastoma progression after *RBI* inactivation.

These WGS data were also used to identify somatic structural variations (SVs), including whole-chromosome gains and losses, focal deletions, insertions, inversions, intrachromosomal rearrangements, interchromosomal rearrangements, and regions of loss of heterozygosity. The average number of SVs was 10 per case, ranging from 0 to 24 events per tumor. One of the tumors exhibited a gain of a region of chromosome 2 spanning *MYCN*; in another tumor, the only chromosomal lesion was a gain of chromosome 6p, which was described above. Overall, the number of SVs was much lower than the number of tumors with genome instability (11).

Retinoblastoma-Associated Single-Nucleotide Polymorphisms

TP53 is rarely mutated in retinoblastoma (46); therefore, other mechanisms of p53 inactivation have been studied, including genomic gain and overexpression of *MDM2* and *MDM4*, two key inhibitors of p53 activity (47–49). The first study to report polymorphisms highly associated with the *MDM2* gene in retinoblastoma patients identified a T > G transversion single-nucleotide polymorphism (SNP) at nucleotide 309 in the *MDM2* promoter (rs2279744) (50). This finding

was corroborated by a later study (51); however, neither of these reports assessed whether this SNP correlated with enhanced transcription of mRNA leading to overexpression of MDM2. In fact, a study evaluating *MDM2* gene expression in 52 human retinoblastoma tumors found that *MDM2* was expressed at low levels in all tumor samples (52). Furthermore, a recent study evaluating the same SNP309 found no correlation between the presence of the SNP and *MDM2* gene and protein expression (53).

As mentioned above, cytogenetic studies of retinoblastoma have indicated that approximately 65% of retinoblastomas have genetic gain of *MDM4* (7, 43). Yet gene expression array analysis of 52 human retinoblastomas showed that *MDM4* was expressed at high levels in all tumors irrespective of the *MDM4* copy number (52). These data suggest that MDM4 expression may be elevated in retinoblastoma through mechanisms that are unrelated to the gene copy number. A genotype study of *MDM4* polymorphisms found a significantly higher frequency of SNP rs116197192G in retinoblastoma patients (51). However, no correlative study with gene and protein expression was performed. A different study examining *MDM4* SNP7 (rs1563828) and SNP34091 (rs4245739) found no significant correlation between SNP7 and *MDM4* gene and protein expression, whereas all samples with SNP34091 A/A allele had high levels of MDM4 protein expression (53). Interestingly, the distribution of MDM4 SNP34091 in this retinoblastoma cohort was not significantly different from that of the general population (53).

Epigenetics and Retinoblastoma

RB1 has been implicated in regulating most major epigenetic processes, including microRNA (miRNA) regulation, DNA methylation, histone modification, and ATP-dependent chromatin reorganization (54–59). A recent study showed for the first time that inactivation of *RB1* deregulates multiple oncogenic and tumor suppressor pathways through epigenetic mechanisms (11) (**Figure 3b**). This epigenetic reprogramming is required for tumorigenesis, and its discovery has led to the identification of novel therapeutic targets against retinoblastoma.

Although the contribution of epigenetic deregulation of cancer pathways has been shown previously, this study in retinoblastoma provided the first example of epigenetics acting as a major driver of cancer in the absence of other genetic lesions (11). Clearly, some retinoblastomas have genetic lesions that may lead to a subtle growth advantage for a subset of tumors, but major genetic lesions that could act as driver mutations were not identified (11). This model could have important implications for cancers other than retinoblastomas and could begin to elucidate the interplay between genetic and epigenetic contributions to tumorigenesis.

MicroRNAs in retinoblastoma. miRNAs encode small noncoding RNA molecules that function in transcriptional and posttranscriptional regulation of gene expression (60). miRNAs function by base-pairing with complementary sequences within mRNA molecules, usually resulting in gene silencing via translational repression or target degradation (61). miRNA deregulation has been associated with several human diseases including retinoblastoma (62–66). Recent studies show several miRNAs as potential candidate components of oncogenic and tumor suppressor networks in retinoblastoma (**Table 1**).

Members of the let-7 family are among the most widely studied tumor suppressor miRNAs. Functionally, let-7 is involved in repressing members of the Ras family, HMGA2, and c-Myc oncogenes (67–70). As for several other cancers, reduced expression of let-7 in retinoblastoma has been reported (71, 72). Furthermore, a significant inverse correlation between let-7 downregulation and HMGA2 overexpression was documented (71). The let-7 family is highly expressed in the retina (71), suggesting that let-7 may be acting as a tumor suppressor by regulation of HMGA2.

Table 1 MicroRNAs differentially expressed in human retinoblastoma

MicroRNA	Method	Reference
let-7e, miR-513, miR-518c, miR-129, miR-198, miR-320, miR-373, miR-492, miR-494, miR-498, miR-503	Microarray analysis	62
miR-34a	qPCR, RT-PCR	65
let-7a, let-7f, miR-2, miR-7, miR-9, miR-16, miR-17a, miR-20a, miR-25, miR-26a, miR-30b, miR-30d, miR-92a, miR-93a, miR-96, miR-99b, miR-101, miR-103, miR-106b, miR-124, miR-143, miR-148b, miR-181a, miR-183, miR-216a, miR-217, miR-378, miR-1246	Microarray analysis	63
let-7c, let-7i, let-7g, miR-10a, miR-10b, miR-28-5p, miR-29a, miR-29b, miR-29c, miR-34a, miR-34b, miR-34c-5p, miR-96, miR-99a, miR-100, miR-124, miR-125b, miR-130a, miR-132, miR-135b, miR-137, miR-142-3p, miR-142-5p, miR-149, miR-181a, miR-182, miR-183, miR-193a-3p, miR-193b, miR-199a-3p, miR-214, miR-224, miR-338-3p, miR-363, miR-374a, miR-375, miR-376a, miR-505	Microarray analysis	66
let-7a, let-7b, let-7c, miR-10a, miR-10b, miR-20a, miR-21, miR-28, miR-29b, miR-30a-3p, miR-30b, miR-30c, miR-30d, miR-99a, miR-99b, miR-100, miR-103, miR-107, miR-124a, miR-125a, miR-125b, miR-133a, miR-136, miR-141, miR-145, miR-146a, miR-155, miR-181a, miR-181b, miR-182, miR-183, miR-190, miR-191, miR-206, miR-210, miR-222, miR-301, miR-302a, miR-302b, miR-320, miR-330, miR-335, miR-342, miR-368, miR-373, miR-380-5p, miR-382, miR-423, miR-433, miR-451, miR-452, miR-491	Microarray analysis	64
miR-17, miR-18a, miR-20b, miR-216a, miR-217, miR-22, miR-224, miR-25, miR-34a, miR-34c-5p, miR-93, miR-106a, miR-106b, miR-129-3p, miR-129-5p, miR-138, miR-139-3p, miR-155, miR-193a-5p, miR-196b, miR-200a, miR-200b, miR-301b, miR-330-5p, miR-342-5p, miR-370, miR-382, miR-429, miR-449a, miR-449b, miR-485-5p, miR-499-5p, miR-504, miR-518f, miR-652, miR-655, miR-758, miR-874, miR-886-5p, miR-889	qPCR	73

Another tumor suppressor miRNA, miR-34a, was identified as differentially expressed in retinoblastoma (65, 73). Studies have demonstrated that p53 transcriptionally activates the miR-34 family (74–77). Loss of miR-34a silencing functions has been identified in several human cancers, making miR-34a an attractive miRNA for therapeutic development (65). Differential expression of miR-34a and miR-34b was observed in two commonly used retinoblastoma cell lines (Y79 and Weri-Rb1) and retinoblastoma tumor samples. This study also suggests that knockdown of miR-34a by anti-miR molecules may result in increased retinoblastoma cell proliferation and chemotherapeutic resistance (65). In support of a role for miR-34a and the p53 pathway, treatment with topotecan in combination with miR-34a inhibition suppressed cell growth in retinoblastoma cells. A combined treatment using topotecan and the p53 activator nutlin-3 led to a similar inhibition of growth (43). Altogether, the evidence supports the notion that miR-34a functions as a tumor suppressor in the normal retina.

One of the best-characterized oncogenic miRNAs is the miR-17~92 cluster (OncomiR-1). miR-17~92 belongs to a highly conserved family of polycistronic miRNA genes, including the miR-106a~363 and miR-106b~25 clusters (78–80). miR-17~92 acts to promote proliferation, inhibit differentiation, increase angiogenesis, and sustain cell survival (81). A recent report on retinoblastoma shows that members of the miR-17~92 cluster are overexpressed in primary tumors and cell lines (63). miR-17~92 is a target gene of E2F, and loss of *RBI* may lead to increased expression of miR-17~92 through derepressed E2F activity (82, 83). Another study using miRNA inhibitors investigated the survival function of miR-17~92 in human retinoblastoma cell lines (RBL15, Weri-Rb1, and Y79) (84). Their results indicated that inactivation of miR-17~92 suppresses retinoblastoma formation in xenografts and that co-silencing of miR-17/20a and p53

cooperatively decreases the viability of human retinoblastoma cells. The authors suggested that retinoblastoma cells might be addicted to high levels of miR-17~92a expression as a result of a synthetic lethal interaction with both p53 and RB pathways. Together, these findings identify miR-17 and miR-20a (from the miR-17~92 cluster) as putative therapeutic targets for the selective prevention and/or treatment of retinoblastoma (84).

Jo et al. (66) investigated the differential expression of miRNAs in retinoblastoma cell lines of different growth patterns and identified other potential miRNA candidates for the treatment of retinoblastoma. In their study, the miRNA expression patterns of the SNUOT-Rb1 cell line, an adherent line with more rapid growth, were compared with those of the Y79 cell line, which displays nonadherent and slower growth (66). Their results show that more than half of the top 10 mRNA targets of miR-10b, miR-29a, miR-29b, miR-29c, and let-7c overexpressed in SNUOT-Rb1 cells, and of miR-34a, miR-34c-5p, miR-124, miR-135b, miR-142-5p, and let-7i overexpressed in Y79 cells, were related to biological processes including cell adhesion, cell cycle, cell death, and cell division, which could affect the growth patterns of cells (66). Altogether, miRNA studies on retinoblastoma have provided novel insights into the pathogenesis of this cancer and potential new therapeutic targets for decreasing oncogenic activity, increasing tumor suppressive functions, and/or promoting differentiation in cancer patients (85).

DNA methylation in retinoblastoma. A role for promoter methylation in retinoblastoma tumorigenesis was first described when methylation of a CpG island (CpG 106) overlapping the *RBI* promoter and exon 1 was discovered in these tumors (86). These initial findings were later confirmed, and hypermethylation of the *RBI* promoter was correlated with decreased gene expression (87, 88). Since then, many studies have reported *RBI* promoter methylation, leading to the first evidence of an epigenetic component in retinoblastoma tumorigenesis (11, 89–91).

Studies on retinoblastoma have also looked at the methylation status of other genes beyond *RBI*. One of the first studies to look at promoter methylation of tumor suppressor genes in retinoblastoma examined the methylation status of nine genes: *p16INK4A*, *MGMT*, *GSTP1*, *RASSF1A*, *APC*, *DAPK*, *RAR β* , *CDH11*, and *CDH13* (92). Of these, *RASSF1A* (RAS-associated domain family 1A) was hypermethylated in 59% of tumors analyzed and *APC* in 6%. Other studies have confirmed the *RASSF1A* results (93); however, a functional relationship remains to be elucidated.

Epigenetic silencing of the gene *O*⁶-methylguanine-DNA methyltransferase (*MGMT*) in retinoblastoma was also investigated (93). Promoter hypermethylation of *MGMT* was found in 15% of the retinoblastoma tumors analyzed. In addition, *MGMT* hypermethylation was associated with advanced-stage retinoblastoma (93). This finding could provide a useful prognostic tool for this disease.

A promoter methylation analysis of the tumor suppressor *p16INK4A* showed hypermethylation in most retinoblastoma tumors that also exhibited p16INK4A protein downregulation (94). Furthermore, in over half of these cases, the same alteration in *p16INK4A* expression was observed in the parents of these patients, suggesting that this alteration could be a novel inheritable susceptibility marker for retinoblastoma (94).

Until recently, promoter methylation analyses had focused on hypermethylation of tumor suppressor genes. To evaluate the general epigenetic landscape, we (11) performed a genome-wide promoter methylation analysis comparing 19 primary retinoblastoma tumor samples with 6 normal fetal retinæ. In this study, we identified 118 genes that were differentially expressed (at least fivefold) and exhibited correlative DNA methylation profiles. Among these, 35 genes showed promoter hypermethylation and gene expression downregulation and 83 genes showed promoter hypomethylation and overexpression (Table 2). Among these 83 genes, we identified *SYK* as a potentially important oncogene in retinoblastoma (discussed below).

Table 2 Genes deregulated by DNA methylation^a

	Gene symbol				
Upregulated	<i>ACOT11</i>	<i>CSTA</i>	<i>KCNS3</i>	<i>RBP4</i>	SYK
	<i>AIF1</i>	<i>CTSS</i>	<i>KCNV2</i>	<i>RBP7</i>	<i>SYNE1</i>
	<i>AKR1C3</i>	<i>CYP27B1</i>	<i>LY6E</i>	<i>RNASE1</i>	<i>TCIRG1</i>
	<i>ANK1</i>	DDB2	<i>LYZ</i>	<i>RNASE6</i>	<i>TFF1</i>
	<i>ARHGAP15</i>	<i>DEFB119</i>	<i>MATN2</i>	<i>ROBO4</i>	<i>TFPI2</i>
	<i>ASTN2</i>	<i>DPP4</i>	<i>MMP9</i>	<i>RS1</i>	<i>TGFBI</i>
	<i>C1S</i>	<i>EPHX1</i>	<i>MS4A6A</i>	<i>SERPINA3</i>	<i>TGM2</i>
	<i>C7</i>	<i>FGL2</i>	<i>MYL9</i>	<i>SGCD</i>	<i>TIMP3</i>
	<i>CAV2</i>	<i>FHL2</i>	<i>PDE6A</i>	<i>SLA</i>	<i>TMEM38A</i>
	<i>CD14</i>	<i>GBP1</i>	<i>PDE6C</i>	<i>SLC16A3</i>	<i>TULP1</i>
	<i>CD302</i>	<i>GIMAP7</i>	<i>PDE6H</i>	<i>SLC29A1</i>	<i>TYROBP</i>
	CD74	<i>GNAT2</i>	<i>PLA2G5</i>	<i>SP100</i>	<i>VMO1</i>
	<i>CEL</i>	<i>GPX3</i>	<i>PPL</i>	<i>SPARCL1</i>	<i>VWF</i>
	<i>CFI</i>	<i>GUCA1A</i>	<i>PRAME</i>	<i>SPINK4</i>	<i>WFDC1</i>
	<i>CHI3L1</i>	<i>GUCA1B</i>	<i>PTGDS</i>	<i>SQRDL</i>	<i>XK</i>
	<i>COL5A1</i>	<i>GUCA1C</i>	<i>PTGS2</i>	<i>STAB1</i>	
<i>CRISPLD2</i>	<i>IFI30</i>	<i>RAC2</i>	<i>STOM</i>		
Downregulated	<i>ADAMTS18</i>	<i>DCX</i>	<i>HRC</i>	<i>PABPC5</i>	<i>SLC18A2</i>
	<i>ANK3</i>	<i>DKK3</i>	<i>GPR85</i>	<i>PCDH20</i>	SOX2
	<i>BCHE</i>	<i>ECEL1</i>	<i>MAB21L2</i>	<i>PLP1</i>	<i>SPON1</i>
	<i>CDH10</i>	<i>ELAVL4</i>	<i>MEG3</i>	<i>RAB31</i>	<i>ST6GAL2</i>
	<i>COL2A1</i>	<i>FOXP2</i>	<i>NR2E3</i>	<i>RBP1</i>	<i>STMN4</i>
	<i>CPNE4</i>	<i>GDPD2</i>	<i>NRXN3</i>	<i>SEZ6L</i>	<i>TAC1</i>
	<i>CUGBP2</i>	<i>GLT25D2</i>	<i>NUAK1</i>	<i>SFRP2</i>	<i>TTYH1</i>

^aCancer genes are in boldface.

Integrative epigenetic analysis of retinoblastoma. Recently, we conducted an integrative epigenetic analysis using chromatin immunoprecipitation-on-chip, DNA methylation analysis, and gene expression arrays to explore whether epigenetic deregulation of genes or pathways promotes tumorigenesis in retinoblastoma (11). We identified 60 genes that were differentially expressed and exhibited correlative histone modifications and DNA methylation profiles. Among these, 10 are known cancer genes, 3 of which are upregulated: *TFF1*, a secreted gastrointestinal mucosa protein overexpressed in some digestive tumors and breast cancers; *SYK*, a novel proto-oncogene; and *MCM5*, a protein important for DNA replication and cell cycle regulation. The downregulated cancer genes are *ASLC1*, a transcriptional regulator involved in the initiation of neuronal differentiation; *CTNND1*, a catenin involved in cell-cell adhesion; *SOX2*, a transcription factor involved in embryonic development and a cause of syndromic microphthalmia; *ADAMTS18*, a putative tumor suppressor; *GLI3*, a transcription factor and mediator of Sonic hedgehog signaling; *PCDH11X*, a member of a subfamily of cadherins; and *DKK1*, an inhibitor of the WNT signaling pathway (11).

One of the most unexpected findings from this study was the importance of SYK in retinoblastoma. This tyrosine kinase is upregulated in retinoblastoma and is required for tumor survival (11). Retinal progenitor cells and retinal neurons express very low levels of SYK, and SYK has no known function in the developing visual system. Moreover, there are no recurrent genetic lesions

in *SYK* in retinoblastoma to suggest that it is an important driver of tumorigenesis (11). Only by integrating epigenetic analyses and gene expression analysis were we able to identify *SYK* as an important oncogene in retinoblastoma. Treatment of retinoblastoma cell lines and animals with established orthotopic xenografts with anti-*SYK* short hairpin RNA or a small-molecule inhibitor of *SYK* reduced tumor growth both in vitro and in vivo (11). This example highlights the value of integrating whole-genome analyses of the genetic and epigenetic features of cancer genomes.

RARE RETINOBLASTOMA GENESIS

Retinoblastoma Without *RB1* Inactivation

Although most retinoblastoma tumors show mutations in both *RB1* alleles (or promoter methylation), a recent report estimated that 2.7% of retinoblastoma tumors present no *RB1* inactivation (95). In 52% of these *RB*^{+/+} tumors, amplification of the *MYCN* oncogene (*RB*^{+/+}*MYCN*^d) was identified as the potential driver of tumor initiation (95) (**Figure 1c**). Furthermore, at least one of these *RB*^{+/+} *MYCN*^d tumors displayed functional RB1 protein (95). The genetic drivers for the remaining *RB*^{+/+} tumors remain to be identified but show frequent gain of 19p, 17p and q, 2p, and the telomeric end of 9q (95). Retrospectively, it is not surprising that *MYCN* is implicated in *RB*^{+/+} retinoblastomas because *MYCN*, like *RB1*, has a role in controlling the activation of the *E2F1*, *E2F3*, and *E2F3* genes (96–98). Interestingly, a *RB*^{+/+}*MYCN*^d tumor showed no genomic aberrations other than the amplification in *MYCN*, similar to that observed in *RB*^{-/-} tumors (11). This finding opens the possibility that, regardless of the initiating mutation, epigenetics is the driver of tumor progression in retinoblastoma and E2F transcriptional targets may mediate this process.

Chromothripsis-Driven Retinoblastoma

Chromothripsis is the phenomenon by which tens to hundreds of genomic rearrangements are acquired in a single catastrophic event in localized and confined genomic regions in one or a few chromosomes (99). We have found that, in a very small percentage of retinoblastoma tumors, the *RB1* gene has been inactivated through a chromothriptic event in chromosome 13 (**Figure 1d**; 100). It remains to be determined whether in these rare cases epigenetics also plays a central role in tumor progression.

CONCLUSIONS

Retinoblastoma represents one of the unusual cancers in which the initiating genetic lesion (*RB1* loss of function) is known. Yet the genetic and epigenetic complexity of retinoblastoma is widely appreciated and evidenced by the intricate network of cellular and epigenetic components that modulate tumor progression. Altogether, the evidence points to a greater role for epigenetic alterations in retinoblastoma. Recent findings highlight how comprehensive genetic and epigenetic analyses of tumors can be integrated to elucidate the mechanisms underlying the progression of retinoblastoma following *RB1* inactivation. These approaches might help uncover the molecular mechanisms of tumor progression and have an impact on the diagnosis and prognosis of, drug response to, and new therapeutic approaches for retinoblastoma.

DISCLOSURE STATEMENT

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.

LITERATURE CITED

1. Knudson AG Jr. 1971. Mutation and cancer: statistical study of retinoblastoma. *PNAS* 68:820–23
2. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, et al. 1986. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature* 323:643–46
3. Dunn JM, Phillips RA, Becker AJ, Gallie BL. 1988. Identification of germline and somatic mutations affecting the retinoblastoma gene. *Science* 241:1797–800
4. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. *Cell* 144:646–74
5. Manning AL, Longworth MS, Dyson NJ. 2010. Loss of pRB causes centromere dysfunction and chromosomal instability. *Genes Dev.* 24:1364–76
6. Hernando E, Nahlé Z, Juan G, Diaz-Rodriguez E, Alaminos M, et al. 2004. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. *Nature* 430:797–802
7. Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, et al. 2008. Loss of *RB1* induces non-proliferative retinoma: Increasing genomic instability correlates with progression to retinoblastoma. *Hum. Mol. Genet.* 17:1363–72
8. Amato A, Lentini L, Schillaci T, Iovino F, Di Leonardo A. 2009. RNAi mediated acute depletion of retinoblastoma protein (pRb) promotes aneuploidy in human primary cells via micronuclei formation. *BMC Cell Biol.* 10:79
9. Iovino F, Lentini L, Amato A, Di Leonardo A. 2006. RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. *Mol. Cancer* 5:38
10. Negrini S, Gorgoulis VG, Halazonetis TD. 2010. Genomic instability—an evolving hallmark of cancer. *Nat. Rev. Mol. Cell Biol.* 11:220–28
11. Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, et al. 2012. A novel retinoblastoma therapy from genomic and epigenetic analyses. *Nature* 481:329–34
12. Zielinski B, Gratias S, Toedt G, Mendrzyk F, Stange DE, et al. 2005. Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. *Genes Chromosomes Cancer* 43:294–301
13. Yan Y, Dunkel IJ, Guan X, Abramson DH, Jhanwar SC, O'Reilly RJ. 2000. Engraftment and growth of patient-derived retinoblastoma tumour in severe combined immunodeficiency mice. *Eur. J. Cancer* 36:221–28
14. Benavente CA, McEvoy JD, Finkelstein D, Wei L, Kang G, et al. 2013. Cross-species genomic and epigenomic landscape of retinoblastoma. *Oncotarget* 4:844–59
15. Squire J, Gallie BL, Phillips RA. 1985. A detailed analysis of chromosomal changes in heritable and non-heritable retinoblastoma. *Hum. Genet.* 70:291–301
16. Squire J, Phillips RA, Boyce S, Godbout R, Rogers B, Gallie BL. 1984. Isochromosome 6p, a unique chromosomal abnormality in retinoblastoma: verification by standard staining techniques, new densitometric methods, and somatic cell hybridization. *Hum. Genet.* 66:46–53
17. Potluri VR, Helson L, Ellsworth RM, Reid T, Gilbert F. 1986. Chromosomal abnormalities in human retinoblastoma. A review. *Cancer* 58:663–71
18. Balaban-Malenbaum G, Gilbert F, Nichols WW, Hill R, Shields J, Meadows AT. 1981. A deleted chromosome no. 13 in human retinoblastoma cells: relevance to tumorigenesis. *Cancer Genet. Cytogenet.* 3:243–50
19. Chaum E, Ellsworth RM, Abramson DH, Haik BG, Kitchin FD, Chaganti RS. 1984. Cytogenetic analysis of retinoblastoma: evidence for multifocal origin and in vivo gene amplification. *Cytogenet. Cell Genet.* 38:82–91
20. Gilbert F, Balaban G, Breg WR, Gallie B, Reid T, Nichols W. 1981. Homogeneously staining region in a retinoblastoma cell line: relevance to tumor initiation and progression. *J. Natl. Cancer Inst.* 67:301–6
21. Cowell JK, Hogg A. 1992. Genetics and cytogenetics of retinoblastoma. *Cancer Genet. Cytogenet.* 64:1–11
22. Hogg A, Onadim Z, Baird PN, Cowell JK. 1992. Detection of heterozygous mutations in the *RB1* gene in retinoblastoma patients using single-strand conformation polymorphism analysis and polymerase chain reaction sequencing. *Oncogene* 7:1445–51
23. Oliveros O, Yunis E. 1995. Chromosome evolution in retinoblastoma. *Cancer Genet. Cytogenet.* 82:155–60

24. Amare Kadam PS, Ghule P, Jose J, Bamne M, Kurkure P, et al. 2004. Constitutional genomic instability, chromosome aberrations in tumor cells and retinoblastoma. *Cancer Genet. Cytogenet.* 150:33–43
25. Corson TW, Gallie BL. 2007. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. *Genes Chromosomes Cancer* 46:617–34
26. Grasemann C, Gratias S, Stephan H, Schüler A, Schramm A, et al. 2005. Gains and overexpression identify *DEK* and *E2F3* as targets of chromosome 6p gains in retinoblastoma. *Oncogene* 24:6441–49
27. Orlic M, Spencer CE, Wang L, Gallie BL. 2006. Expression analysis of 6p22 genomic gain in retinoblastoma. *Genes Chromosomes Cancer* 45:72–82
28. Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, et al. 2004. Amplification and overexpression of *E2F3* in human bladder cancer. *Oncogene* 23:1627–30
29. Oeggerli M, Schraml P, Ruiz C, Bloch M, Novotny H, et al. 2006. *E2F3* is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. *Oncogene* 25:6538–43
30. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, et al. 2004. Transcription factor *E2F3* overexpressed in prostate cancer independently predicts clinical outcome. *Oncogene* 23:5871–79
31. Cooper CS, Nicholson AG, Foster C, Dodson A, Edwards S, et al. 2006. Nuclear overexpression of the *E2F3* transcription factor in human lung cancer. *Lung Cancer* 54:155–62
32. Hu H-G, Scholten I, Gruss C, Knippers R. 2007. The distribution of the *DEK* protein in mammalian chromatin. *Biochem. Biophys. Res. Commun.* 358:1008–14
33. Von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, et al. 1992. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, *dek* and *can*, and the expression of a chimeric, leukemia-specific *dek-can* mRNA. *Mol. Cell. Biol.* 12:1687–97
34. Lin L, Piao J, Gao W, Piao Y, Jin G, et al. 2013. *DEK* over expression as an independent biomarker for poor prognosis in colorectal cancer. *BMC Cancer* 13:366
35. Lillington DM, Kingston JE, Coen PG, Price E, Hungerford J, et al. 2003. Comparative genomic hybridization of 49 primary retinoblastoma tumors identifies chromosomal regions associated with histopathology, progression, and patient outcome. *Genes Chromosomes Cancer* 36:121–28
36. Herzog S, Lohmann DR, Buiting K, Schüler A, Horsthemke B, et al. 2001. Marked differences in unilateral isolated retinoblastomas from young and older children studied by comparative genomic hybridization. *Hum. Genet.* 108:98–104
37. Nakagawa T, Tanaka Y, Matsuoka E, Kondo S, Okada Y, et al. 1997. Identification and classification of 16 new kinesin superfamily (KIF) proteins in mouse genome. *PNAS* 94:9654–59
38. Wang Q, Wang L, Li D, Deng J, Zhao Z, et al. 2013. Kinesin family member 14 is a candidate prognostic marker for outcome of glioma patients. *Cancer Epidemiol.* 37:79–84
39. Thériault BL, Pajovic S, Bernardini MQ, Shaw PA, Gallie BL. 2012. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer. *Int. J. Cancer* 130:1844–54
40. Corson TW, Gallie BL. 2006. *KIF14* mRNA expression is a predictor of grade and outcome in breast cancer. *Int. J. Cancer* 119:1088–94
41. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, Gallie BL. 2007. *KIF14* messenger RNA expression is independently prognostic for outcome in lung cancer. *Clin. Cancer Res.* 13:3229–34
42. Madhavan J, Coral K, Mallikarjuna K, Corson TW, Amit N, et al. 2007. High expression of *KIF14* in retinoblastoma: association with older age at diagnosis. *Investig. Ophthalmol. Vis. Sci.* 48:4901–6
43. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, et al. 2006. Inactivation of the p53 pathway in retinoblastoma. *Nature* 444:61–66
44. Roylance R, Gorman P, Papior T, Wan Y-L, Ives M, et al. 2006. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. *Oncogene* 25:6544–53
45. Laurie N, Mohan A, McEvoy J, Reed D, Zhang J, et al. 2009. Changes in retinoblastoma cell adhesion associated with optic nerve invasion. *Mol. Cell. Biol.* 29:6268–82
46. Kato MV, Shimizu T, Ishizaki K, Kaneko A, Yandell DW, et al. 1996. Loss of heterozygosity on chromosome 17 and mutation of the *p53* gene in retinoblastoma. *Cancer Lett.* 106:75–82
47. Horn HF, Vousden KH. 2007. Coping with stress: multiple ways to activate p53. *Oncogene* 26:1306–16

48. Marine J-C, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. 2006. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. *Cell Death Differ.* 13:927–34
49. Marine J-C, Jochemsen AG. 2004. Mdmx and Mdm2: brothers in arms? *Cell Cycle* 3:900–4
50. Castéra L, Sabbagh A, Dehainault C, Michaux D, Mansuet-Lupo A, et al. 2010. *MDM2* as a modifier gene in retinoblastoma. *J. Natl. Cancer Inst.* 102:1805–8
51. de Oliveira Reis AH, de Carvalho IN, de Sousa Damasceno PB, Ferman SE, Lucena E, et al. 2012. Influence of *MDM2* and *MDM4* on development and survival in hereditary retinoblastoma. *Pediatr. Blood Cancer* 59:39–43
52. McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, et al. 2011. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. *Cancer Cell* 20:260–75
53. McEvoy J, Ulyanov A, Brennan R, Wu G, Pounds S, et al. 2012. Analysis of *MDM2* and *MDM4* single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. *PLOS ONE* 7:e42739
54. Chi P, Allis CD, Wang GG. 2010. Covalent histone modifications—miswritten, misinterpreted and mis-erased in human cancers. *Nat. Rev. Cancer* 10:457–69
55. Lu J, Ruhf M-L, Perrimon N, Leder P. 2007. A genome-wide RNA interference screen identifies putative chromatin regulators essential for E2F repression. *PNAS* 104:9381–86
56. Benetti R, Gonzalo S, Jaco I, Muñoz P, Gonzalez S, et al. 2008. A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl1-dependent regulation of DNA methyltransferases. *Nat. Struct. Mol. Biol.* 15:998
57. Wen H, Andrejka L, Ashton J, Karess R, Lipsick JS. 2008. Epigenetic regulation of gene expression by *Drosophila* Myb and E2F2-RBF via the Myb-MuvB/dREAM complex. *Genes Dev.* 22:601–14
58. Bourgo RJ, Siddiqui H, Fox S, Solomon D, Sansam CG, et al. 2009. SWI/SNF deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. *Mol. Biol. Cell* 20:3192–99
59. Gonzalo S, Blasco MA. 2005. Role of Rb family in the epigenetic definition of chromatin. *Cell Cycle* 4:752–55
60. Chen K, Rajewsky N. 2007. The evolution of gene regulation by transcription factors and microRNAs. *Nat. Rev. Genet.* 8:93–103
61. Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. *Cell* 136:215–33
62. Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, et al. 2009. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. *Child's Nerv. Syst.* 25:13–20
63. Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, et al. 2011. *miR-17~92* cooperates with *RB* pathway mutations to promote retinoblastoma. *Genes Dev.* 25:1734–45
64. Li BQ, Zhang J, Huang T, Zhang L, Cai YD. 2012. Identification of retinoblastoma related genes with shortest path in a protein-protein interaction network. *Biochimie* 94:1910–17
65. Dalgard CL, Gonzalez M, deNiro JE, O'Brien JM. 2009. Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells. *Investig. Ophthalmol. Vis. Sci.* 50:4542–51
66. Jo DH, Kim JH, Park WY, Kim KW, Yu YS. 2011. Differential profiles of microRNAs in retinoblastoma cell lines of different proliferation and adherence patterns. *J. Pediatr. Hematol. Oncol.* 33:529–33
67. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. 2005. *RAS* is regulated by the *let-7* microRNA family. *Cell* 120:635–47
68. Lee YS, Dutta A. 2007. The tumor suppressor microRNA *let-7* represses the *HMGA2* oncogene. *Genes Dev.* 21:1025–30
69. Mayr C, Hemann MT, Bartel DP. 2007. Disrupting the pairing between *let-7* and *Hmga2* enhances oncogenic transformation. *Science* 315:1576–79
70. Sampson VB, Rong NH, Han J, Yang Q, Aris V, et al. 2007. MicroRNA *let-7a* down-regulates *MYC* and reverts *MYC*-induced growth in Burkitt lymphoma cells. *Cancer Res.* 67:9762–70
71. Mu G, Liu H, Zhou F, Xu X, Jiang H, et al. 2010. Correlation of overexpression of *HMGA1* and *HMGA2* with poor tumor differentiation, invasion, and proliferation associated with *let-7* down-regulation in retinoblastomas. *Hum. Pathol.* 41:493–502
72. Huang JC, Babak T, Corson TW, Chua G, Khan S, et al. 2007. Using expression profiling data to identify human microRNA targets. *Nat. Methods* 4:1045–49

73. Martin J, Bryar P, Mets M, Weinstein J, Jones A, et al. 2013. Differentially expressed miRNAs in retinoblastoma. *Gene* 512:294–99
74. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, et al. 2007. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. *Mol. Cell* 26:745–52
75. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. 2007. A microRNA component of the p53 tumour suppressor network. *Nature* 447:1130–34
76. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. 2007. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. *Mol. Cell* 26:731–43
77. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, et al. 2007. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: *miR-34a* is a p53 target that induces apoptosis and G₁-arrest. *Cell Cycle* 6:1586–93
78. Sage J, Ventura A. 2011. miR than meets the eye. *Genes Dev.* 25:1663–67
79. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, et al. 2008. Targeted deletion reveals essential and overlapping functions of the *miR-17~92* family of miRNA clusters. *Cell* 132:875–86
80. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. 2005. A microRNA polycistron as a potential human oncogene. *Nature* 435:828–33
81. Olive V, Jiang I, He L. 2010. *mir-17-92*, a cluster of miRNAs in the midst of the cancer network. *Int. J. Biochem. Cell Biol.* 42:1348–54
82. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, et al. 2007. An E2F/miR-20a autoregulatory feedback loop. *J. Biol. Chem.* 282:2135–43
83. Woods K, Thomson JM, Hammond SM. 2007. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. *J. Biol. Chem.* 282:2130–34
84. Nittner D, Lambert I, Clermont F, Mestdagh P, Köhler C, et al. 2012. Synthetic lethality between Rb, p53 and Dicer or miR-17–92 in retinal progenitors suppresses retinoblastoma formation. *Nat. Cell Biol.* 14:958–65
85. Reis AH, Vargas FR, Lemos B. 2012. More epigenetic hits than meets the eye: microRNAs and genes associated with the tumorigenesis of retinoblastoma. *Front. Genet.* 3:284
86. Greger V, Passarge E, Höpping W, Messmer E, Horsthemke B. 1989. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. *Hum. Genet.* 83:155–58
87. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. 1991. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. *Am. J. Hum. Genet.* 48:880–88
88. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. 1993. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. *Oncogene* 8:1063–67
89. Ohtani-Fujita N, Dryja TP, Rapaport JM, Fujita T, Matsumura S, et al. 1997. Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma. *Cancer Genet. Cytogenet.* 98:43–49
90. Richter S, Vandezande K, Chen N, Zhang K, Sutherland J, et al. 2003. Sensitive and efficient detection of *RBI* gene mutations enhances care for families with retinoblastoma. *Am. J. Hum. Genet.* 72:253–69
91. Livide G, Epistolato MC, Amenduni M, Disciglio V, Marozza A, et al. 2012. Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA. *Pathol. Oncol. Res.* 18:703–12
92. Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, et al. 2002. Aberrant promoter methylation and silencing of the *RASSF1A* gene in pediatric tumors and cell lines. *Oncogene* 21:4345–49
93. Choy KW, Lee TC, Cheung KF, Fan DS, Lo KW, et al. 2005. Clinical implications of promoter hypermethylation in *RASSF1A* and *MGMT* in retinoblastoma. *Neoplasia* 7:200–6
94. Indovina P, Acquaviva A, De Falco G, Rizzo V, Onnis A, et al. 2010. Downregulation and aberrant promoter methylation of *p16INK4A*: a possible novel heritable susceptibility marker to retinoblastoma. *J. Cell. Physiol.* 223:143–50
95. Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, et al. 2013. Characterisation of retinoblastomas without *RBI* mutations: genomic, gene expression, and clinical studies. *Lancet Oncol.* 14:327–34
96. Sears R, Ohtani K, Nevins JR. 1997. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. *Mol. Cell. Biol.* 17:5227–35
97. Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. 2000. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. *Mol. Cell. Biol.* 20:3633–39

98. Leone G, Sears R, Huang E, Rempel R, Nuckolls F, et al. 2001. Myc requires distinct E2F activities to induce S phase and apoptosis. *Mol. Cell* 8:105–13
99. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, et al. 2011. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell* 144:27–40
100. McEvoy J, Nagahawatte P, Finkelstein D, Richards-Yutz J, Valentine M, et al. 2014. RB1 gene inactivation by chromothripsis in human retinoblastoma. *Oncotarget* 5(2):438–50



Contents

The Roles of Cellular and Organismal Aging in the Development of Late-Onset Maladies <i>Filipa Carvalhal Marques, Yuli Volovik, and Ebud Cohen</i>	1
Driver and Passenger Mutations in Cancer <i>Julia R. Pon and Marco A. Marra</i>	25
Leukocyte Chemoattractant Receptors in Human Disease Pathogenesis <i>Brian A. Zabel, Alena Rott, and Eugene C. Butcher</i>	51
Pathobiology of Transfusion Reactions <i>James C. Zimring and Steven L. Spitalnik</i>	83
The Emerging Picture of Autism Spectrum Disorder: Genetics and Pathology <i>Jason A. Chen, Olga Peñagarikano, T. Grant Belgard, Vivek Swarup, and Daniel H. Geschwind</i>	111
SWI/SNF Chromatin Remodeling and Human Malignancies <i>Julien Masliab-Planchon, Ivan Bièche, Jean-Marc Guinebretière, Franck Bourdeaut, and Olivier Delattre</i>	145
The Role of Endoplasmic Reticulum Stress in Human Pathology <i>Scott A. Oakes and Feroz R. Papa</i>	173
Engineered In Vitro Disease Models <i>Kambez H. Benam, Stephanie Dauth, Bryan Hassell, Anna Herland, Abbisbek Jain, Kyung-Jin Jang, Katia Karalis, Hyun Jung Kim, Luke MacQueen, Roza Mahmoodian, Samira Musab, Yu-suke Torisawa, Andries D. van der Meer, Remi Villenave, Moran Yadid, Kevin K. Parker, and Donald E. Ingber</i>	195
A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma <i>Ian J. Frew and Holger Moch</i>	263

Emerging Concepts in Alzheimer’s Disease <i>Harry V. Vinters</i>	291
AA Amyloidosis: Pathogenesis and Targeted Therapy <i>Gunilla T. Westermark, Marcus Fändrich, and Per Westermark</i>	321
Hepatitis C Virus–Associated Cancer <i>Ming V. Lin, Lindsay Y. King, and Raymond T. Chung</i>	345
Diseases of Pulmonary Surfactant Homeostasis <i>Jeffrey A. Whitsett, Susan E. Wert, and Timothy E. Weaver</i>	371
The Inflammasomes and Autoinflammatory Syndromes <i>Lori Broderick, Dominic De Nardo, Bernardo S. Franklin, Hal M. Hoffman, and Eicke Latz</i>	395
DNA Replication Stress as a Hallmark of Cancer <i>Morgane Macheret and Thanos D. Halazonetis</i>	425
Birth and Pathogenesis of Rogue Respiratory Viruses <i>David Safronetz, Heinz Feldmann, and Emmie de Wit</i>	449
Protein Glycosylation in Cancer <i>Sean R. Stowell, Tongzhong Ju, and Richard D. Cummings</i>	473
Pathobiology of Severe Asthma <i>Humberto E. Trejo Bittar, Samuel A. Yousem, and Sally E. Wenzel</i>	511
Genetics and Epigenetics of Human Retinoblastoma <i>Claudia A. Benavente and Michael A. Dyer</i>	547
Indexes	
Cumulative Index of Contributing Authors, Volumes 1–10	563
Cumulative Index of Article Titles, Volumes 1–10	567
Errata	
An online log of corrections to <i>Annual Review of Pathology: Mechanisms of Disease</i> articles may be found at http://www.annualreviews.org/errata/pathol	



ANNUAL REVIEWS

It's about time. Your time. It's time well spent.

Now Available from Annual Reviews:

Annual Review of Virology

virology.annualreviews.org • Volume 1 • September 2014

Editor: **Lynn W. Enquist**, Princeton University

The *Annual Review of Virology* captures and communicates exciting advances in our understanding of viruses of animals, plants, bacteria, archaea, fungi, and protozoa. Reviews highlight new ideas and directions in basic virology, viral disease mechanisms, virus-host interactions, and cellular and immune responses to virus infection, and reinforce the position of viruses as uniquely powerful probes of cellular function.

Complimentary online access to the first volume will be available until September 2015.

TABLE OF CONTENTS:

- *Forty Years with Emerging Viruses*, C.J. Peters
- *Inventing Viruses*, William C. Summers
- *PHIRE and TWiV: Experiences in Bringing Virology to New Audiences*, Graham F. Hatfull, Vincent Racaniello
- *Viruses and the Microbiota*, Christopher M. Robinson, Julie K. Pfeiffer
- *Role of the Vector in Arbovirus Transmission*, Michael J. Conway, Tonya M. Colpitts, Erol Fikrig
- *Balance and Stealth: The Role of Noncoding RNAs in the Regulation of Virus Gene Expression*, Jennifer E. Cox, Christopher S. Sullivan
- *Thinking Outside the Triangle: Replication Fidelity of the Largest RNA Viruses*, Everett Clinton Smith, Nicole R. Sexton, Mark R. Denison
- *The Placenta as a Barrier to Viral Infections*, Elizabeth Delorme-Axford, Yoel Sadovsky, Carolyn B. Coyne
- *Cytoplasmic RNA Granules and Viral Infection*, Wei-Chih Tsai, Richard E. Lloyd
- *Mechanisms of Virus Membrane Fusion Proteins*, Margaret Kielian
- *Oncolytic Poxviruses*, Winnie M. Chan, Grant McFadden
- *Herpesvirus Genome Integration into Telomeric Repeats of Host Cell Chromosomes*, Nikolaus Osterrieder, Nina Wallaschek, Benedikt B. Kaufert
- *Viral Manipulation of Plant Host Membranes*, Jean-François Laliberté, Huanquan Zheng
- *IFITM-Family Proteins: The Cell's First Line of Antiviral Defense*, Charles C. Bailey, Guocai Zhong, I-Chueh Huang, Michael Farzan
- *Glycan Engagement by Viruses: Receptor Switches and Specificity*, Luisa J. Ströh, Thilo Stehle
- *Remarkable Mechanisms in Microbes to Resist Phage Infections*, Ron L. Dy, Corinna Richter, George P.C. Salmond, Peter C. Fineran
- *Polydnaviruses: Nature's Genetic Engineers*, Michael R. Strand, Gaelen R. Burke
- *Human Cytomegalovirus: Coordinating Cellular Stress, Signaling, and Metabolic Pathways*, Thomas Shenk, James C. Alwine
- *Vaccine Development as a Means to Control Dengue Virus Pathogenesis: Do We Know Enough?* Theodore C. Pierson, Michael S. Diamond
- *Archaeal Viruses: Diversity, Replication, and Structure*, Nikki Dellas, Jamie C. Snyder, Benjamin Bolduc, Mark J. Young
- *AAV-Mediated Gene Therapy for Research and Therapeutic Purposes*, R. Jude Samulski, Nicholas Muzyczka
- *Three-Dimensional Imaging of Viral Infections*, Cristina Risco, Isabel Fernández de Castro, Laura Sanz-Sánchez, Kedar Narayan, Giovanna Grandinetti, Sriram Subramaniam
- *New Methods in Tissue Engineering: Improved Models for Viral Infection*, Vyas Ramanan, Margaret A. Scull, Timothy P. Sheahan, Charles M. Rice, Sangeeta N. Bhatia
- *Live Cell Imaging of Retroviral Entry*, Amy E. Hulme, Thomas J. Hope
- *Parvoviruses: Small Does Not Mean Simple*, Susan F. Cotmore, Peter Tattersall
- *Naked Viruses That Aren't Always Naked: Quasi-Enveloped Agents of Acute Hepatitis*, Zongdi Feng, Asuka Hirai-Yuki, Kevin L. McKnight, Stanley M. Lemon
- *In Vitro Assembly of Retroviruses*, Di L. Bush, Volker M. Vogt
- *The Impact of Mass Spectrometry-Based Proteomics on Fundamental Discoveries in Virology*, Todd M. Greco, Benjamin A. Diner, Ileana M. Cristea
- *Viruses and the DNA Damage Response: Activation and Antagonism*, Micah A. Luftig

ANNUAL REVIEWS | Connect With Our Experts

Tel: 800.523.8635 (US/CAN) | Tel: 650.493.4400 | Fax: 650.424.0910 | Email: service@annualreviews.org



Annual Rev. Pathol. Mech. Dis. 2015.10:547-562. Downloaded from www.annualreviews.org by Dr. Claudia Benavente on 01/28/15. For personal use only.